Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy

Fig. 7

N-803 + αPD-L1 combination promotes the generation of an immunostimulatory milieu in the serum. Mice were implanted with 4T1 tumors as in Fig. 1 and treated on days 9 and 13 with N-803 and/or αPD-L1 on days 9, 11, and 13. Serum was obtained at days 14 and 21 post-tumor implant and analyzed for level of IFNγ (a), TNFα (b), IL-10 (c), and IL-6 (d). Level of serum cytokines from individual animals at day 14 (left panels) and curves showing kinetics of serum cytokine levels (right panels) show mean ± SD. Data are combined from 2 experiments, n = 4–5 mice/group per experiment

Back to article page